Navigation Links
Replidyne Terminates Faropenem Agreements
Date:6/23/2008

LOUISVILLE, Colo., June 23 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) today announced that it has decided to terminate its license agreement with Asubio Pharma Co., Ltd. for faropenem medoxomil (faropenem). In conjunction with this decision, the Company also announced that it has terminated its supply agreement with Asubio Pharma Co., Ltd. and Nippon Soda Co. Ltd. for production of faropenem. These decisions were made as a result of the Company being unable to secure a partner for the faropenem program. As previously announced, Replidyne had discontinued clinical development of faropenem pending the outcome of discussions with potential partners for the program.

As a result of today's decision, the Company expects to incur charges of up to Japanese Yen 440 million (approximately $4.1 million), consisting of a license termination fee of up to Japanese Yen 375 million (approximately $3.5 million) to Asubio Pharma Co., Ltd. and the reimbursement of engineering costs under its supply agreement of up to Japanese Yen 65 (approximately $0.6 million) to Nippon Soda Co. Ltd. Replidyne will also pay Nippon Soda Co. Ltd. Japanese Yen 99 million (approximately $0.9 million) for delay compensation related to the period from January 1, 2008 through the termination of its supply agreement.

"We are clearly disappointed that we have been unable to identify a partner for the faropenem program," stated Kenneth J. Collins, President and Chief Executive Officer of Replidyne. "We have decided to terminate this program in order to preserve cash and focus our attention on our previously discussed strategic initiatives and our C. difficile Infection (CDI) program and novel anti-infective programs based on DNA replication inhibition tec
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Replidyne to Report First Quarter 2008 Earnings
2. Replidyne Announces 2007 Fourth Quarter and Full Year Results
3. Replidyne to Report 2007 Fourth Quarter and Year-End Earnings
4. Replidyne to Announce Third Quarter 2007 Earnings
5. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
6. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
7. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
8. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
9. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
10. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
11. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... PAT and QbD remains a field that still lacks ... Pharma IQ across the PAT and QbD community it was  found ... not implementing PAT/QbD was due to a lack of personnel with ... opens its doors to industry specialists from the PAT and QbD ...
... Germany, October 11, 2011 joimax® opened ... patronage of the German Academy for Neurosurgery (GANS) and ... Neurosurgery at the "Städtisches Klinikum" in Karlsruhe, Prof. Dr. ... place in Karlsruhe, South Germany, October 5 to 8. ...
... Oct. 11, 2011 STAAR Surgical Company (NASDAQ: STAA ) ... quarter ended September 30, 2011 on Monday, October 24, 2011 ... will host a conference call on Monday, October 24, 2011 ... to discuss the Company,s third quarter results and recent corporate ...
Cached Biology Technology:Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 3STAAR Surgical Announces Third Quarter 2011 Results Release Date and Conference Call 2
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Dec. 17, 2012 The University of Houston (UH) ... thanks to a computer hardware donation from Total, a ... nodes that will occupy four racks of space. ... computing resources," said Jaspal Subhlok, chairman of UH,s department ...
... December 2012)New research released today, on the eve of an ... agencies and investors for a growing spate of violent clashes ... of resources from the rural poor to investors is underway, ... Top global experts at the meeting noted as well that ...
... up on snack foods may increase cancer risk in ... cancers. Published early online in CANCER , a ... suggests that an eating pattern low in snack foods ... syndromelower their risk. Lynch syndrome is an inherited ...
Cached Biology News:Total donates high-speed computer cluster to UH 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 3New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 4Snack attack: Eating unhealthy snack foods may affect cancer risk in patients with Lynch syndrome 2
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: